Biggest News Aggregation in the World
📰 Aloctocogene News

Aloctocogene News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Aloctocogene. Real-time updates on events, politics, business and more.

BioMarin Pharmaceutical Inc.: BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A

European Commission Approval Expected Q3 2022 First Gene Therapy for Treatment of Hemophilia A Recommended for Approval in Europe More than 20,000 Adults with Severe, Hemophilia
Nordrhein Westfalen Hank Fuchs Johannes Oldenburg University Clinic In Bonn European Commission Biomarin Pharmaceutical Inc

BioMarin: Phase 1/2 Study On Hemophilia A Shows Hemostatic Control With Valoctocogene Roxaparvovec

BioMarin: Phase 1/2 Study On Hemophilia A Shows Hemostatic Control With Valoctocogene Roxaparvovec WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN), in an update on phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, said Wednesday that the safety profile of valoctocogene roxaparvovec in the study remains consistent with previously reported data with no delayed-onset treatment related adverse events. The company...
United States Biomarin Pharmaceutical Inc Marin Pharmaceutical Marketing Authorization Application European Medicines Agency Biologics License Application

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science